Evidence comparison

Rapamycin (Sirolimus) vs Metformin

How they actually compare on the evidence — trial volume, literature, mechanism, and our honest confidence grade. Higher counts reflect research attention, not proof of superiority.

Western · mTOR inhibitor · prescription

Rapamycin (Sirolimus)

雷帕霉素

75Confidence

Extensive human-trial evidence

RCTs: 2,105
Meta: 635
Trials: 2,358

Key active: Rapamycin / sirolimus (mTOR inhibitor)

Gold-standard animal lifespan data; human longevity off-label, early

mTOR inhibition extends lifespan across yeast, worms, flies, and mice more reproducibly than any other intervention; human longevity use is off-label and dosing/safety (the PEARL trial and others) is the open question.

Full Rapamycin (Sirolimus) evidence →

Western · Biguanide · prescription

Metformin

二甲双胍

78Confidence

Extensive human-trial evidence

RCTs: 3,523
Meta: 1,317
Trials: 3,064

Key active: Metformin (biguanide)

Large clinical use; longevity endpoint trial (TAME) pending

Metformin activates AMPK and dampens hepatic glucose output; observational data hint at lower age-related disease in diabetics, and the landmark TAME trial is designed to test whether it slows aging endpoints in non-diabetics.

Full Metformin evidence →

Need this for a decision?

Get a custom dossier comparing your shortlist.

We build evidence-graded comparisons for formulators, brands, clinics, and investors.

Commission research

Informational only — not medical advice or a recommendation to take either. Trial and literature counts are registry/database matches and include endpoints beyond longevity. See each ingredient page for sources.